TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03983174

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drainage seton with flap
Description: Seton is placed around the external sphincter then mucosal advancement flap will be constructed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EAS sparing seton
Description: Rerouting of the seton around the internal sphincter only sparing the external sphincter
Study: NCT03251274

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: machine bathing
Description: machine bathing 20-min duration at evening

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional bathing
Description: traditional bathing
Study: NCT01718470

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube
Description: Hemodynamic variables were recorded at 8 moments: baseline, in the operating room one minute before anesthetic induction; 5 minutes after the end of surgery before awakening (ETT group) and 1, 5, 10, 15, 30 and 60 min after extubation . The last blood pressure and heart rate measurements were taken in the postoperative recovery room.
Study: NCT00935337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Bridging Program
Description: Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene
Description: treatment as usual
Study: NCT00050583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Ten Weekly Sessions of Manualized CBT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Cognitive Behavioral Therapy
Study: NCT02098304

Intervention type: DEVICE
Group type: OTHER
Intervention: Calcivis Caries Activity Imaging System
Description: Teeth imaged with the Calcivis Caries Activity Imaging System
Study: NCT00692003

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zonisamide
Description: 25-400 mg capsules orally once daily in the evening.~Maximum study duration of 28 weeks comprising:~Baseline Period (Week-8/-4 to Week 0) no treatment~Titration Period (Week 0 to Week 4) \<12 years old: 1 mg/kg; \>= 12 years old: 50 mg daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)~Down Titration Period (4 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25-400 mg Zonisamide Placebo capsules orally once daily in the evening.~Maximum study duration of 28 weeks comprising:~Baseline Period (Week-8/-4 to Week 0) no treatment~Titration Period (Week 0 to Week 4) \<12 years old: 1 mg/kg Zonisamide Placebo; \>= 12 years old: 50 mg Zonisamide Placebo capsules daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4~Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)~Down Titration Period (4 weeks)
Study: NCT00771173

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenazopyridine HCl
Description: Phenazopyrdine HCl 200 mg q8h x 24
Study: NCT04072653

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SLNB is spared
Description: SLNB is spared in patients with negative preoperative axillary assessment(including LymphPET and other imaging examinations)
Study: NCT01535287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Active study agent: Dexmedetomidine at 1 microgram/kilogram Intramuscular (IM) Placebo study agent: Same volume as the study drug of placebo (normal saline).~All blinding, labeling, preparation, storage of agents done by the pharmacist. The drug will be administered into the deltoid muscle by using a TB syringe attached to a 3/4 inch length and 25 Gauge width needle by anesthesia provider after the induction of general anesthesia by the anesthesia provider.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: Active study agent: Dexmedetomidine at 1 microgram/kilogram Intramuscular (IM) Placebo study agent: Same volume as the study drug of placebo (normal saline).~All blinding, labeling, preparation, storage of agents done by the pharmacist. The drug will be administered into the deltoid muscle by using a TB syringe attached to a 3/4 inch length and 25 Gauge width needle by anesthesia provider after the induction of general anesthesia by the anesthesia provider.
Study: NCT04016701

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Floreo Joint Attention Module
Description: Two sessions per week for eight weeks of the Floreo VR Joint Attention Module, delivered via a Google Cardboard compatible VR headset. Each session includes one or two 5-minute VR episodes and an intermission that is at least 3 minutes long

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regularly Scheduled Therapy
Description: therapy as regularly scheduled at therapy center
Study: NCT04616937

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: GOS
Description: Prebiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00771173

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet administered q8 hours for 24 hours postop.
Study: NCT00700895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin Sodium
Description: All predicted warfarin dose will be administered by rounding down to the nearest 0.5 mg. Warfarin (Marevan®) is available as 1mg (brown), 3 mg (blue) and 5 mg (pink) oral tablets from GlaxoSmithKline Pte. Ltd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin Sodium
Description: All predicted warfarin dose will be administered by rounding down to the nearest 0.5 mg. Warfarin (Marevan®) is available as 1mg (brown), 3 mg (blue) and 5 mg (pink) oral tablets from GlaxoSmithKline Pte. Ltd.
Study: NCT01462448

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Single blood draw of 30 ml

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Single blood draw of 30 ml
Study: NCT01586806

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Only
Description: This is the control treatment arm. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine with 1 mg of Dexamethasone
Description: This is one of two treatment arms. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic), mixed with 1 mg of dexamethasone. Total injection volume will be 15 ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine with 4 mg of Dexamethasone
Description: This is one of two treatment arms. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic), mixed with 4 mg of dexamethasone. Total injection volume will be 15 ml.
Study: NCT03409029

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI Scan
Description: Additional imaging using MRI scan
Study: NCT00992186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carlumab
Description: Carlumab diluted in 5 percent (%) dextrose administered at the dose of 15 milligram per kilogram (mg/kg) by intravenous (into a vein) infusion (a fluid or a medicine delivered into a vein by way of a needle) at a constant rate over a 90 minute period once every 2 weeks until disease progression.
Study: NCT01718470

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LMA
Description: Hemodynamic variables were recorded at 8 moments: baseline, in the operating room one minute before anesthetic induction; 5 minutes after the end of surgery before tube replacement (LMA group); and 1, 5, 10, 15, 30 and 60 min after LMA removal. The last blood pressure and heart rate measurements were taken in the postoperative recovery room.
Study: NCT00166270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate 2000
Study: NCT04156620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: The subjects will receive secukinumab 6 mg/kg i.v. at randomization (Baseline (BSL) visit), followed by the administration of secukinumab 3 mg/kg i.v. every four weeks starting at Week 4 through Week 48 (exposure through Week 52)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects will receive i.v. placebo at randomization (BSL visit), Weeks 4, 8, and 12 , followed by the administration of secukinumab 3 mg/kg i.v. at Week 16 and every four weeks through Week 48 (exposure through Week 52)
Study: NCT01957566

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: APS
Study: NCT02724865

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Somnodent® (Oral appliance therapy)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Herbst® (Oral appliance therapy)
Study: NCT02755610

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PD Product Check List
Description: PD Product Check List was developed based on the 28 routine steps of standard orientation manual for new Thai PD patients. Of these, step 2 (weighting the PD solution bag), step 3 (checking expiration date, volume, glucose concentration, clarity, and color, step 27 (weighting the PD solution bag), and step 28 (recording time, volume, and any abnormality encountered) are relevant to product defect report.
Study: NCT01829217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Study: NCT01841528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fresh embryo transfer
Description: rFSH/GnRH antagonist will be administered for ovarian stimulation. Oocyte pick-up will be performed when at least two follicles ≥18mm. Two fresh embryos will be transferred at Day 3. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum HCG will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: frozen-thawed embryo transfer
Description: rFSH/GnRH antagonist will be administered for ovarian stimulation. Oocyte pick-up will be performed when at least two follicles ≥18mm. All embryos will be vitrified in fresh cycle, and at least 2 embryos should be frozen at Day 3. Two months later, two thawed Day 3 embryos will be transferred with HRT (hormone replacement therapy) prepared endometrium. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum HCG will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
Study: NCT01153477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Monitoring and Counseling - Enhanced
Description: Calls or in-person sessions, 1x weekly for first 8 weeks, then every other week up to a year. Step up session frequency if needed based on participants' ratio of protective and risk factors.
Study: NCT00003077

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid
Study: NCT04611178

Intervention type: DEVICE
Intervention: Mechanical thrombectomy
Description: Stent retriever for treatment of cerebral arterial occlusions
Study: NCT04354155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin Prefilled Syringe [Lovenox]
Description: Twice-daily low-dose enoxaparin thromboprophylaxis (starting dose, 0.5 m/gkg subcutaneously q12 hours, adjusted to achieve a 4 hour post-dose anti-factor Xa level of 0.20-0.49 anti-Xa U/mL)
Study: NCT02147821

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Pleural Chest Tube
Study: NCT02878083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEDOLIZUMAB
Description: Infusion at week 0 week 2 week 6 week 14 for all patients Infusion at week 22 for responder patient only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADALIMUMAB
Description: For nonresponder patients only : Injection at week 22 week 24 week 26 and week 28
Study: NCT03601390

Intervention type: DEVICE
Intervention: PET/CT and EBV DNA
Description: PET/CT and EBV DNA will be proformed after the IMRT treatment
Study: NCT02727322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin
Description: Patients will receive nitrofurantoin 100mg once daily or a placebo. Pills will be identical.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00614133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous nutrition with glucose and amino acids
Description: Glucose and amino acids intravenously starting 20 hours before the operation until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient's measured resting energy expenditure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous nutrition with glucose and amino acids.
Description: Glucose and amino acids intravenously starting with surgical skin incision until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient's measured resting energy expenditure.
Study: NCT02898922

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae
Description: 20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae
Description: 20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China
Study: NCT00772278

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: carotid artery stenting
Description: carotid artery angiography, angioplasty and stenting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: carotid endarterectomy
Description: open surgery including endarterectomy
Study: NCT01936233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 0.1 QD po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: LAminvudine 0.1 QD po

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine
Description: LAminvudine 0.1 QD po
Study: NCT01336348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: 60 mg loading dose given orally at presentation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirofiban
Description: Tirofiban will be given at high bolus dose only of bolus followed by 2 H infusion in a randomized manner (1:1 ratio).
Study: NCT02246491

Intervention type: OTHER
Group type: OTHER
Intervention: A-T iPS cell line
Description: Reprogramming A-T patients iPS cell line

Intervention type: OTHER
Group type: OTHER
Intervention: Carrier patients iPS cell line
Description: Reprogramming iPS cell line from carrier patients
Study: NCT05124717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin, prolonged-release tablets 500 mg (JSC Farmak, Ukraine)
Description: One tablet of the Test product was administered orally with 240 mL of water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage® XR 500 mg prolonged release tablets (Merck Serono Ltd, UK)
Description: One tablet of the Reference product was administered orallyn with 240 mL of water.
Study: NCT04749745

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-theanine
Description: The subject will receive paired-pulse TMS (ppTMS) procedure before and 30min after taking the drug orally, to assess motor cortex excitability, measured by surface electromyogram (EMG). The ppTMS procedure is administered by a TMS stimulator controlled a program software named Signal. The coil of the stimulator is placed above the scalp where the stimulation would activate the left primary motor cortex region that controls the right thumb. When a pulse stimulation is delivered by the coil, the EMG over a thumb muscle (abductor pollicis brevis) will record a motor-evoked potential on the tracing. Cross-over with placebo in two separate sessions at least 72 hours apart.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-theanine
Description: The subject will receive paired-pulse TMS (ppTMS) procedure before and 30min after taking the drug orally, to assess motor cortex excitability, measured by surface electromyogram (EMG). The ppTMS procedure is administered by a TMS stimulator controlled a program software named Signal. The coil of the stimulator is placed above the scalp where the stimulation would activate the left primary motor cortex region that controls the right thumb. When a pulse stimulation is delivered by the coil, the EMG over a thumb muscle (abductor pollicis brevis) will record a motor-evoked potential on the tracing. Cross-over with placebo in two separate sessions at least 72 hours apart.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The subject will receive paired-pulse TMS (ppTMS) procedure before and 30min after taking the drug orally, to assess motor cortex excitability, measured by surface electromyogram (EMG). The ppTMS procedure is administered by a TMS stimulator controlled a program software named Signal. The coil of the stimulator is placed above the scalp where the stimulation would activate the left primary motor cortex region that controls the right thumb. When a pulse stimulation is delivered by the coil, the EMG over a thumb muscle (abductor pollicis brevis) will record a motor-evoked potential on the tracing. Cross-over with L-theanine in two separate sessions at least 72 hours apart.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subject will receive paired-pulse TMS (ppTMS) procedure before and 30min after taking the drug orally, to assess motor cortex excitability, measured by surface electromyogram (EMG). The ppTMS procedure is administered by a TMS stimulator controlled a program software named Signal. The coil of the stimulator is placed above the scalp where the stimulation would activate the left primary motor cortex region that controls the right thumb. When a pulse stimulation is delivered by the coil, the EMG over a thumb muscle (abductor pollicis brevis) will record a motor-evoked potential on the tracing. Cross-over with L-theanine in two separate sessions at least 72 hours apart.
Study: NCT04313738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: Home visit, health education
Study: NCT02061475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Patches
Study: NCT03225482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivationally Enhanced Compensatory Cognitive Training
Description: ME-CCT is a manualized group-based behavioral intervention (8 weeks, 2 hours per week, 20 hours total) designed to improve cognitive and everyday functioning in patients with MCI.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Goal-focused Supportive Contact
Description: SC is a group therapy intervention that provides the same frequency and amount of therapist and other group member contact as ME-CCT, but does not provide training in cognitive strategies, lifestyle strategies, or motivational enhancement. The SC intervention focuses on setting and achieving short or long-term goals.
Study: NCT03007771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance-guided High-Intensity Focused Ultrasound
Description: -Heating will not be performed in two areas of the body near each other (for example, not heating in two different places of the same thigh) to minimize the risk of overheating any one part of the subject's body. Heating a second target site is not mandatory, even if time allows, and the participant may refuse.
Study: NCT02125955

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic fiber
Description: Dissolved in water.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dissolved in water
Study: NCT02136914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADS-5102
Description: Oral capsules to be administered once nightly at bedtime, for 25 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules to be administered once nightly at bedtime, for 25 weeks
Study: NCT02312648

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interventional Group
Description: Respiratory exercises will be performed and subsequently active upper limb exercises will be conducted (flexion-extension and adduction-abduction) of large joints (shoulder, elbow and wrist) Associated with upper limb exercises, patients will undergo a series of exercises ergometer with lower limb (LL). The mobilization will be conducted on a cycle ergometer in an active, lasting 20 minutes, divided into three steps: heat 5 minutes; 10 minutes of low intensity exercise, with a speed of 30 revolutions per minute (rpm); and 5 minutes recovery. The patient remains in the supine position with the head of the bed elevated to 45 degrees, while the lower limbs will remain planned. After positioning the patient, the ergometer is adjusted.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The patients will oriented to maintain sitting position and perform deep breaths (3 sets of 10 repetitions) in each session. They will receive the intervention once a day, for 30 minutes until 7th postoperative day. In addition, non invasive ventilation will be installed after orotracheal extubation for 30 to 60 minutes.
Study: NCT01720394

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cervical Ripening Balloon, Cook Medical Inc.
Description: Application of the cervical ripening double-balloon (filled with 2x 80ml) on day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dinoprostone
Description: Application of Propess-vaginal-insert, (Dinoprostone 10mg - Ferring Arzneimittel Ges.m.b.H., 1100 Vienna, Austria) for labor induction on day 1-3 in therapy arm 2.
Study: NCT01493089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zegerid
Description: 20 mg Zegerid suspension to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losec
Description: 20 mg Losec capsule to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days.
Study: NCT00830050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: 500 mg BID 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID 7 days